NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Coronavirus
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to...
Predictmedix AI Rebrands as QScreen AI Inc., (QAI) Harnessing Quantum-AI Synergy for Health Screening
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP0) (formerly Predictmedix AI Inc.),...
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE)...
Predictmedix AI Inc. Selected by Canadian Government for Mexico Trade Mission, Led by Minister Dominic LeBlanc, to Drive Growth and High-Value Partnerships
Participation in Canada's official trade mission provides Predictmedix with exclusive, government-facilitated introductions to Mexican distributors, clients, and industry leaders, accelerating...
Predictmedix AI Inc. Selected by Canadian Government for Mexico Trade Mission, Led by Minister Dominic LeBlanc, to Drive Growth and High-Value Partnerships
Participation in Canada's official trade mission provides Predictmedix with exclusive, government-facilitated introductions to Mexican distributors, clients, and industry leaders, accelerating...
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave – NV-387 is Effective Against H3N2
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
Seasoned leader with global commercialization and marketing expertiseSOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc....
Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare
Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or...
Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare
Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or...
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate...
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025...
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of...
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of...
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker...
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker...
Predictmedix AI Inc – 2025 Year End Corporate Update
A Defining Year Positioning Predictmedix AI at the Convergence of Quantum, AI, and HealthcareToronto, Ontario--(Newsfile Corp. - December 17, 2025)...
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH...
Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or...
Services PMI® at 52.6%; November 2025 ISM® Services PMI® Report
Business Activity Index at 54.5%; New Orders Index at 52.9%; Employment Index at 48.9%; Supplier Deliveries Index at 54.1%TEMPE, Ariz.,...